A previous report found that neuroendocrine neoplasm patients with lower pre-treatment activation state (CD69 expression) of naïve T cells and NK cells were associated with longer progression-free survival after anti-PD-1 immunotherapy (MacFarlane et al., 2021). Here, PDCD1 is linked to neuroendocrine neoplasm.